GLP-1 weight-loss drugs linked to “low” but real risk of hair loss, study finds
A study published in The BMJ indicates that GLP-1 receptor agonists, used for diabetes and weight loss, are associated with a low but statistically significant risk of hair loss. Researchers suggest that while the risk is rare and often reversible, it remains a factor for patients to consider when starting treatment.
Why it matters
As the popularity of weight-loss drugs like semaglutide grows, understanding potential side effects is crucial for patient informed consent and long-term adherence.
Glucagon-like peptide-1 (GLP-1) receptor agonists, mainly used to treat type 2 diabetes and obesity, are associated with a significantly higher risk of hair loss than other diabetes medications, according to a new study published in The BMJ. While rare, some people taking semaglutide and tirzepatide have reported hair loss. The new study confirms the low risk of hair loss, with authors arguing that this can help make better informed decisions.Importantly, the most observed cases of hair loss linked to GPL-1 were reversible, as hair follicles remained intact, the authors said.“Although the absolute risk of clinically recorded alopecia associated with GLP-1 receptor agonist use is low, the observed association may still influence patients’ satisfaction, adherence, and decisions to start or continue therapy,” authors wrote.The researchers analysed electronic records of patients on medication for type 2 diabetes, including GLP-1 and two other alternative diabetes drugs: SGLT-2 inhibitors and DPP-4 inhibitors.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in